Extremely high avidity association of Fe(III) with the sickle red cell membrane

Blood

Volumn 88, Issue 1, 1996, Pages 349-352

  Shalev, Oded ^a   Hebbel, Robert P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXY 6 NAPHTHALENESULFONIC ACID; 8 QUINOLINOL; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; APOTRANSFERRIN; CATECHOL; CATECHOL DERIVATIVE; CHELATING AGENT; CITRIC ACID; DEFERIPRONE; DEFEROXAMINE; EDETIC ACID; FERRIC ION; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; NITRILOTRIACETIC ACID; PENTETIC ACID; TROPOLONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ERYTHROCYTE GHOST; HUMAN; HUMAN CELL; IRON CHELATION; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

EID: 0029982812     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.349.349     Document Type: Article

References (14)

1. Hebbel RP: The sickle erythrocyte in double jeopardy: Autoxidation and iron decompartmentalization. Semin Hematol 27:51, 1990
2. Kuross SA, Hebbel RP: Nonheme iron in sickle erythrocyte membranes: Association with phospholipids and potential role in lipid peroxidation. Blood 72:1278, 1988
3. Hartley A, Rice-Evans C: Membrane-associated iron-species and membrane oxidation in sickle-cell disease. Biochem Soc Trans 17:488, 1989
4. Repka T, Shalev O, Reddy R, Yuan J, Abrahamov A, Rachmilewitz EA, Low PS, Hebbel RP: Nonrandom association of free iron with membranes of sickle and β-thalassemic erythrocytes. Blood 82:3204, 1993
5. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH: Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 70:1253, 1982
6. Repka T, Hebbel RP: Hydroxyl radical formation by sickle erythrocyote membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. Blood 78:2753, 1991
7. Thunberg T: Occurrence and significance of citric acid in the animal organism. Physiol Rev 33:1, 1953
8. Sugihara T, Repka T, Hebbel RP: Detection, characterization and bioavailability of membrane-associated iron in the intact sickle red cell. J Clin Invest 90:2327, 1992
9. Martell AE: The design and synthesis of chelating agents, in Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. Elsevier, North Holland, 1981, p 67
10. Aisen P, Leibman A, Zweier J: Stiochiometric and site characteristics of the binding of iron to human transferrin. J Biol Chem 253:1930, 1978
11. Kontoghiorghes GJ: Structure/iron binding activity of 1-hydroxypyrid-2-one chelators intended for clinical use. Inorg Chim Acta 135:145, 1987
12. Pitt CG: Structure and activity relationships of iron chelating drugs, in Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. Elsevier, North Holland, 1981, p 105
13. Timberlake CF: Iron-malate and iron-citrate complexes. J Chem Soc (Lond), 5078, 1964
14. Tu AT, Heller MJ: Structure and stability of metal-nucleoside phosphate complexes, in Sigel H (ed): Metal Ions in Biological Systems, vol 1, Simple Complexes. New York, NY, Dekker, 1974, P2